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Available online 5 March 2008Mesenchymal stem cells (MSCs) residing within the bone marrow (BM) differentiate into
multiple lineages, including fat, bone, and cartilage. BecauseMSCs aremultipotent and have
a great capacity to be expanded in vitro, these cells are an attractive candidate for clinical
applications to repair or regenerate damaged tissues of mesenchymal origin. However,
application of MSCs to muscle degenerative diseases has been hampered by the poor
differentiation of MSCs into the muscle lineage. To date most methods require the presence
of strong non-physiological agents, such as azacytidine. In the present study we explored
the potential of Pax3, the master regulator of the embryonic myogenic program, to promote
myogenic differentiation from MSCs. Our results clearly demonstrate that Pax3 promotes
the differentiation of MSCs towards the myogenic lineage, which occurs at the expense of
other mesenchymal lineages including fat, bone, and cartilage. This effect is cell type-
selective since Pax3 overexpression in endothelial cells fails to promote myogenesis. These
results highlight the potential of regulating transcriptional pathways to direct
differentiation of adult stem cells.
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In the last decade, a number of studies have pointed to the
existence of cells within the bone marrow (BM) endowed with
muscle regenerative potential [1–6]. Initial studies by Ferrari
et al. [1] demonstrated that BM cells were capable of migrating
from circulation and participate in the regeneration process of
damaged muscle fibers in cardiotoxin-injured immunodefi-
cient mice. This finding was followed by a number of reports
documenting engraftment after BM transplantation into
dystrophic mice [2–4,7]. Although these results were encoura-
ging, overall the levels of engraftment were low with less than
1% of total muscle fibers being donor-derived [2,7], and thus
unlikely to provide functional benefit. Since the studiesestern.edu (R.C.R. Perling
er Inc. All rights reserveddescribed above have involved the transplantation of both
whole BM [7], which contains a heterogeneous cell population,
or highly purified hematopoietic stem cells (BM SP cells) [2],
one could hypothesize that such low engraftment was due to
the use of a cell population with limited muscle potential.
Mesenchymal stem cells (MSCs), which reside within the
stromal compartment of adult BM, have been identified as a
non-hematopoietic stem cell population capable of self-
renewal and multi-lineage differentiation into mesenchymal
lineages, including bone, fat, cartilage, and connective tissue
[8–10]. Although less than 0.01% of the BM mononuclear
cell fraction comprises MSCs [10], their easy isolation, rapid
expansion andmulti-lineage differentiation draw attention to
their therapeutic potential in regenerativemedicine and tissueeiro).
.
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pocytes or osteoblasts), skeletal myoblasts have not been
easily differentiated from MSCs. Initial induction protocols to
differentiate MSCs into myogenic progenitors have employed
5-azacytidine [11], a strong demethylating agent associated
with muscle gene activation, in particular MyoD [12–14]. The
drawback of this non-physiological method is excessive cell
death, which results in virtually none [15] or very few surviving
cells that are then endowed with myogenic features (not
shown). A more reasonable approach consists of culturing
MSCs with myoblasts [16] or myoblast-conditioned medium
[15]. Recently, galectin-1 has been identified as a soluble factor
present inmyoblast-conditionedmedium, that has the capacity
to promote myogenic conversion of dermal fibroblasts [17] and
fetal MSCs [15]. This conversion seems to occur via activation of
themyogenic regulatory factors (MRFs), including Myf-5, MyoD,
and myogenin [15], as observed during embryonic myogenesis
[18–20]. Another reported approach [21] made use of activated
Notch to generate skeletal muscle cells from human MSCs.
Although the results were somewhat encouraging, the ratio-
nale for using Notch1 was not made clear.
During embryogenesis, all skeletal muscles, except for
those of the head are derived from transient condensations
of paraxial mesoderm, the somites, located next to the neural
tube and notochord [22]. Signals from these structures lead to
patterning of the somite to form the sclerotome, a precursor for
the skeleton, and the dermomyotome, the precursor for both
dermis and muscle [22,23]. Cells expressing the transcription
factor Pax3 within the dermomyotome migrate medially
through the dorsomedial lip of the dermomyotome to form
an epithelial sheet, known as the myotome [24]. At this site
myogenesis occurs [25,26] upon activation of MRFs, including
Myf-5, Mrf4, MyoD, and myogenin. Since the role of Pax3 up-
streamofMRFs is essential for embryonicmuscle specification
[18,19,24,27–30], we investigated the potential of Pax3 to drive
myogenesis from a murine MSC as well as its effects on other
mesenchymal lineages.Materials and methods
Cell lines and culture conditions
MSCB9, a murine mesenchymal stem cell line generated in our
laboratory as previously described [31] was used for the experi-
ments. These cells weremaintained inMSC expansionmedium
consisting of low-glucose Dulbecco's modified Eagle's medium
(LG-DMEM; Invitrogen) supplemented with 40% Molecular Cell
Developmental Biology (MCDB)-201 medium (Sigma), 10% fetal
bovine serum (FBS, Invitrogen), 1× insulin–transferrin–selenium
(ITS; Sigma), 1× linoleic-acid–bovine serum-albumin (Sigma),
10−8Mdexamethasone (Sigma), 10−4Mascorbic acid2-phosphate
(Sigma), 50 U/ml penicillin/streptomycin (Invitrogen) and the
following growth factors: 10 ng/ml of recombinant human
platelet-derived growth factor-BB (hPDGF-BB; R&D Systems),
10 ng/ml of recombinant murine epidermal growth factor
(mEGF; Sigma), and 1000 U/ml of recombinant murine leukemia
inhibitory factor (LIF, Chemicon). BEND3, a mouse endothelial
cell line (generously provided by Dr. R. Brekken, UT South-
western Medical Center), and NIH 3T3 fibroblasts were main-tained in LG-DMEM supplemented with 10% FBS, 2 mM L-
glutamine (Invitrogen) and antibiotics. Medium was changed
twice a week. For sub-culture, cells were trypsinized with 0.25%
Trypsin–EDTA (Invitrogen) and replated at a subcultivation ratio
of 1:3. C2C12 cells [32] were used as positive control for gene
expression analyses. Terminal differentiation was induced by
platingC2C12cells at 8×104 cells per cm2ongelatinizeddishes in
2% horse serum (HS) (Atlanta Biologicals) for 4 days.
Retroviral infection and purification of GFP+ cells
MSCV-Pax3iresGFP was created by sub-cloning the cDNA for
Pax3 obtained from pSPORT-Pax3 (Open Biosystems) into
pMSCViresGFP as an EcoR I/Xho I fragment.MSCV-Pax3iresGFP
or MSCViresGFP (control vector) were transfected into 293T
cells using FuGENE6 Transfection Reagent (Roche Diagnostics)
as recommended by the manufacturer. Virus-containing
supernatant was collected 48 h after transfection and filtered
through 0.45 μm filter before use. Approximately 4×105 MSCB9
cells were suspended in 5 ml of viral supernatant containing
10 ng/ml hPDGF-BB, 10 ng/ml mEGF, 1000 U/ml mLIF and 8 μg/
ml hexadimethrin bromide (polybrene; Sigma). Cellswere then
transferred to 6-well plates and centrifuged at 2500 rpm for
90 min at 33 °C on a Hettich centrifuge. After an overnight
incubation at 37 °C with 5% CO2 in air, supernatant was
removed and changed with fresh MSC expansion medium
(10 ng/ml hPDGF-BB, 10 ng/ml mEGF, 1000 U/ml mLIF), as
described above. A similar approach was used for BEND3 and
NIH3T3cells, except for the culturemediumwhichconsistedof
LG-DMEM supplemented with 10% FBS. Two days following
infection, cells were harvested and analyzed on a FACS Aria
(Becton-Dickinson) for GFP expression. Propidium iodide (1 μg/
ml; Pharmingen) was used to exclude dead cells. For purifica-
tion, infected cells were sorted based on the gating of GFP+ on
the fluorescein isothiocyanate (FITC) channel.
Induction of multi-lineage differentiation in vitro
For myogenic differentiation, cells were cultured for up to
3 weeks in several muscle induction conditions as follows: LG-
DMEM supplemented with 10% fetal bovine serum, MSC
expansion medium containing no growth factors, LG-DMEM
supplemented with a mixture of 5% horse serum (HS) and 10%
fetal bovine serum, and LG-DMEM supplemented with 5% or
2% horse serum. Multinucleated myotubes were observed
under phase contrast microscope (Olympus). For adipogenic
differentiation, cells were plated in the presence of Minimum
Essential Medium (MEM) Alpha medium containing horse
serum (12.5%), fetal bovine serum (12.5%), penicillin/strepto-
mycin (50 U/ml), 2-mercaptoethanol (10−4M; Sigma), and
hydrocortisone (10−4M; StemCell Technologies). Formation of
lipid vacuoles in the cells was visualized by Oil Red O staining.
For osteogenic differentiation, cells were cultured in the
presence of DMEM medium with fetal bovine serum (10%),
penicillin/streptomycin (50 U/ml), ascorbic acid 2-phosphate
(50 μmol/l), dexamethasone (0.1 μmol/l), and β-glycerolpho-
sphate (10mmol/l; Sigma). Characterizationwas performed by
Alizarin Red S staining, which detects calcium deposition.
For chondrogenesis, cells were cultured as pellets at a density
of 3×105 cells/ml in serum free-chemically defined medium
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selenium, 1× linoleic-acid–bovine serum-albumin, ascorbic
acid 2-phosphate (50 μg/ml), dexamethasone (100 nM) and
10 ng/ml hTGF β1 (R&D Systems). Medium was changed every
two days. Paraffin-embedded pellet cultures were fixed with
10% formalin, dehydrated and cut into 5 μm-thick sections.
Alcian Blue staining was used to detect cartilage formation.
Reverse transcriptase polymerase chain reaction (RT-PCR)
Analysis
Total RNA was isolated using Trizol (Invitrogen) as recom-
mended by themanufacturer. First strand cDNAwas produced
using Superscript II reverse transcriptase (Invitrogen) with
Oligo dT. 5% of first strand reaction was used for each ensuing
PCR reaction. Primer sequences and PCR conditions are
described in Table 1. For real time PCR, all probe sets were
acquired from Applied Biosystems.
Immunofluorescence staining of cultured cells
Briefly, cells on coverslips were fixed in 4% paraformaldehyde/
PBS and permeabilized with 0.3% Triton X-100 (Sigma) for
15 min at room temperature. Cells were then incubated over-
night at 4°C with primary antibodies including Pax3 (R&D
systems), MyoD (BD Biosciences), myogenin (BD Biosciences),
and MHC (Developmental Studies Hybridoma Bank). A Cy3Table 1 – Mouse primer sequences information for reverse tra
Gene Primer pair sequence
β-actin GTGGGGCGCCCCAGGCACCA
CTCCTTAATGTCACGCACGATTTC
MGB ACCATGGGGCTCAGTGATGGGGAG
CAGGTACTTGACCGGGATCTTGTGC
MyoD GACAGGACAGGACAGGGAGG
GCACCGCAGTAGAGAAGTGT
Myf5 TGAATGTAACAGCCCTGTCTGGTC
CGTGATAGATAAGTCTGGAGCTGG
MRF4 CTGAAGACTGCTGGAGGC
CTACATTGAGCGTCTACA
Myogenin AGAGGAAGTCTGTGTCGGTG
GTAGGCGCTCAATGTACTGG
PPARγ-2 GGAGATTCTCCTGTTGACCCAG
GGCACTCAATGGCCATGAG
LPL TTAACTACCCCCTAGACAACGTCCA
AAGAGATGAATGGAGCGCTCG
Adipsin AGACCCCTACCCTTGCAATACG
TGTTACCATTTGTGATGTTTTCGATC
OPN TGGAGATCGAATTCTGCTTG
TCAAGTGCTTGAGGGCATAC
Cbfa-1 AGTAGCCAGGTTCAACGATCTGA
GGACCGTCCACTGTCACTTTAATA
Coll II GGCAACAGCAGGTTCACATA
CCACACCAAATTCCTGTTCA
Agg CTAAGTTCCAGGGTCACTGTTACCG
TCCTCTCCGGTGGCAAAGAAGTTG
Coll X AAGGAGTGCCTGGACACAAT
GTCGTAATGCTGCTGCCTAT
MGB,myoglobin; MRF4,myogenic regulatory factor 4; PPAR-γ2, peroxisome
bindingprotein-alpha; LPL, lipoprotein lipase; OPN, osteopontin; Cbfa-1, co(Jackson Immunoresearch Laboratories) secondary antibody
was used. DAPI (4,6-diamidino-2-phenylindole; Fluka) was
used to counter-stain nuclei. Fusion index was defined as the
percentage of nuclei belonging to MHC-positive cells with
three or more nuclei. Isotype control antibodies were used as
negative control staining. Immunofluorescent signals were
captured and analyzed using a fluorescence microscope
(Olympus) and MetaVue5.0 software.
Western blot
Western blots were performed using the following antibodies:
mouse anti-MyoD (BD Biosciences), mouse monoclonal anti-
Pax3 (R&D Systems), andmousemonoclonal anti-actin (Sigma).Results
Pax3 directs MSCB9 cells toward the myogenic lineage
Toevaluate the effect of Pax3 on the differentiation ofMSCs into
the myogenic lineage, we transduced Pax3 into the mesench-
ymal stem cell line MSCB9 [31]. One week after retroviral
infection, MSCB9-Pax3 cultures contained cells with elongated
morphology (Fig. 1A, left panel), which was not observed in
control vector-transduced MSCB9 cells (MSCB9-Vector) (Fig. 1A,
right panel). To obtain a homogeneous population of Pax3-nscription-PCR
Annealing temperature (°C) Product size (bp)
50 520
55 318
50 359
50 256
50 235
50 177
65 403
50 388
50 376
50 720
50 137
55 166
59 270
55 461
proliferator-activated receptor gamma 2; C/EBP-α, CCAAT/enhancer-
re-binding factor-1, Coll II, collagen II; Agg, aggrecan; Coll X, collagenX.
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new retroviral infection and FACS sorted the GFP+ cells at 2 days
post-infection (Fig. 1B, upper panel). Remarkablemorphological
changes were observed uniquely in MSCB9-Pax3 cultures, in
which cells aggregated and formed multinucleated rod-like
structures (Fig. 1B, lower left). Consistently, immunofluores-
cence and gene expression analyses showed that MSCB9-Pax3cells expressed Pax3 (Fig. 1C) as well as its downstream
myogenic regulatory factors (MRFs) including MyoD, Myf5, and
to a lesser extent myogenin (Figs. 1C–D). MHC (myosin heavy
chain) and MCK (muscle creatine kinase), markers of terminal
muscle differentiation, were not detected (Figs. 1C–D, respec-
tively). Western Blot analyses further corroborate the expres-
sion of Pax3 andMyoD in these cells (Fig. 1E). On the other hand,
Fig. 2 – Myogenic induction of MSCB9-Pax3 cells.
(A) Morphology of MSCB9-Pax3 and MSCB9-Vector cells
growing under expansion (control) and muscle induction
(differentiation) conditions for three weeks, and (B) Gene
expression analysis for myogenic markers in MSCB9-Pax3
and MSCB9-Vector cells growing under the following culture
conditions: #1— LG-DMEM containing 10% FBS; #2— MSC
expansion medium containing no GFs; #3— LG-DMEM
supplemented with 5% HS and 10% FBS; #4— LG-DMEM
supplemented with 5% HS only. Myotubes differentiated
from C2C12 cells were used as positive control. Scale bar is
100 μm.
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theMRFs (Figs. 1C–E). These data suggest that Pax3 is capable of
driving MSCs towards the muscle lineage through activation of
MRFs.
MSCB9-Pax3 cells were able to differentiate in vitro into
multinucleatedmyotubes simply by the withdrawal of growth
factors from the MSC expansion medium whereas MSCB9-
Vector cells were not (condition 2; Figs. 2A–B). A similar effect
was also observed when cells were cultured in DMEM 10% FBS
(condition 1; Figs. 2 and 3A). Further real time PCR and immu-
nofluorescence analyses of cells growing under this condition
(Figs. 3B–E) revealed that while Pax3 expression remains
unaffected, an overall up-regulation of the MRFs, MyoD,
Myf5, and Myogenin, as well as the terminal differentiation
markers, MCK and MHC, are observed in MSCB9-Pax3 cells
(Figs. 3B–D) when compared to cultures left to confluence in
MSC expansion medium (Figs. 3B–D). Consistent with the
morphological observation of myotube formation, fusion
index was elevated in MSCB9-Pax3 cells (Fig. 3E). In contrast,
MSCB9-Vector cells were negative for all myogenic markers
under thismuscle differentiation condition (Figs. 3B–D). Taken
together, these results suggest that Pax3-transducedMSCs are
capable of undergoing terminal muscle differentiation in vitro.
Pax3 blocks adipogenesis, osteogenesis and chondrogenesis of
MSCs
Given that MSCB9 cells or MSCB9-Vector cells easily make
adipocytes when cultured at a high density (Fig. 4A. ii), the
finding of a total absence of fat formation in MSCB9-Pax3 cells
under these confluent conditions (Fig. 4A.i) led us to hypothe-
size that Pax3 might direct MSCs towards the skeletal muscle
lineage at the expense of the adipogenic lineage. To investi-
gate whether Pax3 is in fact blocking adipogenesis, we cul-
tured MSCB9-Pax3 cells in adipogenic medium. As expected,
the majority of MSCB9-Vector cells differentiated into lipid
vacuoles-containing adipocytes which were visualized by Oil
Red O staining (Fig. 4A.iv). In contrast, no adipocytes but a few
multinucleated myotubes were found in MSCB9-Pax3 cells
(Fig. 4A.iii). These results support the hypothesis that Pax3
might prevent the differentiation of MSCs into the adipogenic
lineage. The emerging question is whether Pax3 is capable of
blocking the other two mesenchymal lineages, specifically
osteogenesis and chondrogenesis. To address this question
we subjected MSCB9-Pax3 as well as MSCB9-Vector cells to
osteogenic and chondrogenic induction medium for up to
4 weeks. Accordingly, MSCB9-Vector control cells differen-Fig. 1 – Pax3 initiates themyogenic program ofMSCs. (A) Morpho
in monolayer culture in MSC expansion medium. (B) Upper pane
MSCB9-Vector cells two days after retroviral infection. Channel d
axis. GFP+ cells were sorted according to represented gates and cu
of these cells 2 days post-sorting. (C) (i) Immunofluorescent stain
Myogenin, and MHC in red (Cy3); Cells are co-stained with DAPI
expressing these myogenic markers. Data are mean>300 cells).
MSCB9-Pax3 and MSCB9-Vector cells. RNA was isolated from the
markers by real time RT-PCR, in which transcripts were normali
independent experiments. (E) Western blot analysis for Pax3 and
shown. Scale bar is 100 μm (A–C).tiated robustly into osteoblasts and chondrocytes (Fig. 4A.vi
and A.viii, respectively) whereas MSCB9-Pax3 cells failed to
differentiate into these lineages (Fig. 4A.v and A.vii). These
findings were corroborated by gene expression analyses for
multi-lineage-specific genes (Fig. 4B). Upon appropriate induc-
tion, MSCB9-Vector cells were positive for all the examinedlogy ofMSCB9-Pax3 andMSCB9-Vector (control) cells growing
l: FACS profile for GFP expression in MSCB9-Pax3 and
etecting GFP is indicated on x axis, and autofluorescence on y
ltured in MSC expansion medium. Lower panel: Morphology
ing of MSCB9-Pax3 and MSCB9-Vector cells: Pax3, MyoD,
(blue); and (ii) Graph representing the percentage of cells
(D) Gene expression analysis for myogenic markers in
se cells and analyzed for the expression of specific myogenic
zed to GAPDH. Error bars indicate standard deviation from 3
MyoD expression in MSCB9-Pax3 and MSCB9-Vector cells is
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Fig. 4 – Pax3 drives MSCs toward the myogenic lineage at the expense of adipogenic, osteogenic and chondrogenic lineages.
(A) Multi-lineage differentiation of MSCB9-Pax3 and MSCB9-Vector cells: Cells were subjected to several conditions as follows,
(i,ii) MSC expansion medium at high cell density— MSCB9-Vector cells present lipid vacuoles as evidenced by Oil Red O
staining; (iii, iv) Adipogenic induction medium— fat formation was characterized by Oil Red O staining; (v,vi) Osteogenic
induction medium— bone formation was evidenced by Alizarin Red S, which stains calcium deposition in the extracellular
matrix; (vii,viii); Chondrogenic induction medium— cartilage formation was characterized by Alcian Blue staining. Scale bar is
100 μm. (B) RT-PCR analysis for lineage-specific genes in MSCB9-Vector and MSCB9-Pax3 cells growing under adipogenic,
osteogenic, chondrogenic, and muscle induction conditions.
1727E X P E R I M E N T A L C E L L R E S E A R C H 3 1 4 ( 2 0 0 8 ) 1 7 2 1 – 1 7 3 3markers for fat, bone and cartilage but not for muscle (Fig. 4B).
On the other hand, MSCB9-Pax3 cells expressed only muscle-
specific genes while markers for other mesenchymal lineages
were absent (Fig. 4B). These results suggest that Pax3 drives the
commitment of MSCs toward the myogenic lineage at the ex-
pense of the adipogenic, osteogenic and chondrogenic lineages.Fig. 3 – Characterization of final myogenic differentiation of Pax
MSCB9-Vector cells growing under expansion (control) and musc
(B) their respective gene expression profile for myogenic markers
GAPDH. Error bars indicate standard deviations from two indepe
(C) Immunofluorescent staining of MSCB9-Pax3 andMSCB9-Vecto
Myogenin, and MHC in red (Cy3); Cells are co-stained with DAPI
expressing Pax3, MyoD, or Myogenin, or in a cytoplasm positive
5 representative pictures (200×) were analyzed and the percentage
(E) Graph showing the fusion index of MSCB9-Pax3 cells. Cells we
percentage of nuclei belonging to MHC-positive cells with three
5 representative pictures were analyzed and the percentage of po
number of multinucleated myotubes was significantly increased
Differentiation experiments were performed in triplicate. Scale bCan Pax3 drive any cell type towards the muscle lineage?
Since our results show a potent effect of Pax3 in driving the
differentiation ofMSCs towards themyogenic lineage, we next
inquired whether Pax3 could drive other cell types to muscle
commitment. For this, we examined the effect of Pax33-modified MSCs. (A) Morphology of MSCB9-Pax3 and
le induction (differentiation) conditions for three weeks, and
by real time RT-PCR, in which transcripts were normalized to
ndent experiments performed in duplicate.
r cells grown undermuscle induction condition: Pax3, MyoD,
(blue); (D) Graph representing the percentage of nuclei
for MHC. Data are mean±SE. For each cell fraction,
of positive cells was calculated among total cells (>300 cells).
re stained for MHC (ii) and the fusion indexwas defined as the
or more nuclei. Data are mean±SE. For each cell fraction,
sitive cells was calculated among total cells (>300 cells). The
in the induced group (p=0.015, two tailed t-test).
ar is 100 μm (A and C).
Fig. 5 – Effect of Pax3 overexpression in endothelial and fibroblast cell lines. (A) Upper panel: Morphology of endothelial
(BEND3) (i) and fibroblast (NIH 3T3) cells (ii) two days after retroviral infection with MSCV-Pax3iresGFP or control vector
MSCViresGFP. Middle panel: FACS profile for GFP expression in BEND3 (i) and NIH 3T3 (ii) cells transduced with Pax3 or control
vector two days after retroviral infection. Channel detecting GFP is indicated on x axis, and autofluorescence on y axis. GFP+ cells
were sorted according to represented gates and cultured in MSC expansion medium. Lower panel: Morphology of these cells
2 days after sorting. (B) Immunofluorescent staining shows nuclear expression of Pax3 only in BEND3-Pax3 and NIH 3T3-Pax3
(red) but not in their respective controls (vector). DAPI staining in blue. (C) Relative levels of MyoD, Myf5, Myogenin, andMCK by
real time RT-PCR. Transcripts are normalized to GAPDH. Error bars indicate standard deviation from 3 independent
experiments. (D)Western blot for Pax3 andMyoD expression in these cell lines.MSCB9 cells were used as reference. Scale bar is
100 μm (A–B).
1728 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 4 ( 2 0 0 8 ) 1 7 2 1 – 1 7 3 3transduction in a mouse endothelial cell line (BEND3) and in a
mouse fibroblast cell line (NIH 3T3). Both cell lines were
subjected to retroviral infection with MSCV-Pax3ireGFP or
vector control MSCViresGFP, as previously described for
MSCB9. No morphological changes were observed two days
following infectionwith either cell line, BEND3 (Fig. 5A.i, upper
panel) or NIH 3T3 (Fig. 5A.ii, upper panel), at which pointFig. 6 – Effect of myogenic induction in Pax3-transduced endothe
and (C) NIH 3T3 cellswere cultured under expansion (control, #0) o
supplementedwith 10% FBS; #2, MSC expansionmedium containi
(i) Representative morphology of these cells after three weeks in cu
under the culture conditions described above. cDNA fromMSCB9-
standard deviations from two independent experiments performe
#2 were analyzed byWestern blot for MyoD expression. MSCB9 cecells were sorted based on GFP expression (Fig. 5A.i–ii, middle
panel). Even after this purification step, there were no
apparentmorphological differences between Pax3-transduced
and Vector-transduced cells in BEND3 or NIH 3T3 cell lines
(Fig. 5A.i–ii, lower panel). Immunofluorescence staining and
western blot analyses confirmed that Pax3 was indeed
expressed in Pax3-transduced cells (Fig. 5B and, respectively).lial and fibroblast cell lines. (A) MSCB9 for reference, (B) BEND3
r severalmuscle induction conditions, as follows: #1, LG-DMEM
ng no growth factors; #3, LG-DMEM supplementedwith 2%HS.
lture; (ii) Real time RT-PCR analysis of respective cells cultured
Pax3 cells was used as positive control. Error bars indicate
d in duplicate. (D) Differentiated cells growing under condition
lls were used as reference. Scale bar is 100 μm (A–C).
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and NIH 3T3-Pax3 cells growing in the absence of any muscle-
inducing agent using MSCB9-Pax3 cells as reference (Fig. 5C).
MyoD andMyf5 RNAswere found inMSCB9-Pax3 andNIH 3T3-Pax3 cells although at much lower levels in the latter (Fig. 5C),
and were not present in BEND3-Pax3 cells (Fig. 5C). Myogenin
and MCK, markers of terminal skeletal muscle differentiation
could be detected in NIH 3T3-Pax3 cells but at insignificant
1730 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 4 ( 2 0 0 8 ) 1 7 2 1 – 1 7 3 3levels under this condition (data not shown). At the protein
level, MyoD was detectable only in MSCB9-Pax3 cells (Fig. 5D).
Thus, despite Pax3 overexpression, BEND3 cells do not seem to
have acquired any potential to differentiate towards the
muscle lineage while NIH 3T3 cells display limited muscle
differentiation potential.To confirm this assumption, we attempted to induce
muscle differentiation of BEND3 and NIH 3T3 cells in vitro by
testing several conditions as previously described (Fig. 2B).
Muscle differentiation induction of MSCB9-Pax3 and MSCB9-
Vector cells were used as positive and negative control,
respectively (Fig. 6A). Consistently with our previous results,
Fig. 8 – Pax3 effects are independent of Notch. Real time PCR for Hes1 and Hes5 (downstream targets of Notch) in MSCB9-Pax3
andMSCB9-Vector cells growing underMSC expansionmedium, adipogenic and osteogenic culture conditions. Transcripts are
normalized to GAPDH. Error bars indicate standard deviations from two independent experiments performed in duplicate.
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these conditions (Fig. 6A.i). Myogenic markers including
MyoD, Myf5, myogenin, and MCK were detected in MSCB9-
Pax3 but not in MSCB9-Vector cells (Fig. 6A.ii). No signal for
these genes was detected in BEND3 cells, despite Pax3 over-
expression (Fig. 6B.ii) in accordance with the lack of morpho-
logical changes (Fig. 6B.i). Since the levels of Pax3 were not as
high in BEND3 cells as in MSCB9 and NIH 3T3 cells (Fig. 5D), we
submitted BEND3-Pax3 cells with a second round of infection
with Pax3. Regardless of higher expression of Pax3 (Fig. 7A),
myogenic regulatory factors were still absent (Figs. 7B–C).
These results indicate that Pax3 is not able to initiate the
myogenic program in endothelial cells. On the other hand,
expression of MRFs could be easily detected in NIH 3T3-Pax3
cells, in particular under condition 2 (Fig. 6C.ii). Although this
induction did not result in significant morphological changes,
MyoD could be detected at the protein level. This finding is not
surprising since fibroblasts are the main cell type of stromal
tissues, and belong to the mesenchymal compartment. Taken
together, these results suggest that Pax3 promotes the muscle
commitment only in specific cell types, in particular those of
mesenchymal origin.Discussion
During mouse embryogenesis, Pax3 is first expressed in the
presomitic mesoderm. This expression is maintained in the
somitic epitheliumof the dermomyotome, and later on (10.5 d.
p.c.) in the myotome [33,34]. Pax3 is also present in the brain,
dorsally throughout the neural tube and in neural crest cells.
Accordingly, Splotch (Pax3-null) mice die by E14.5 due to a
number of developmental defects including impaired neural
tube closure, defects in neural crest-derived structures, failureFig. 7 – Expression of myogenic markers in BEND3-Pax3 cells su
re-infected with retrovirus prepared using MSCV-Pax3iresGFP. GF
MSC expansion medium (control, #0). (A) Western blot analysis f
expression analysis for myogenic markers in BEND3 Pax3 cells g
these cells one week post-sorting and analyzed for the expressio
transcripts were normalized to GAPDH. (C) This gene expression
myogenic induction for 21 days. Real time RT-PCR analysis of re
conditions, as follows: #1, LG-DMEM supplemented with 10% FB
#3, LG-DMEM supplemented with 2% HS. Error bars in (B) and (C
experiments performed in duplicate. cDNA from MSCB9-Pax3 ceof cells within the dermomyotome to delaminate, and there-
fore, absence of limb muscles [24,35,36]. This later defect is
associated with a lack of migratory muscle progenitors, which
prevents MyoD activation by Myf5 and Mrf4 [20,28,36,37].
Because of this important role in muscle specification, Pax3
is considered a master regulator of the embryonic myogenic
program [24,27].
Here we demonstrate that expression of Pax3 in a murine
mesenchymal stem cell line enables the activation of the myo-
genic program in these cells. As observed during embryogenesis,
Pax3 does so by activating downstream muscle-specific genes,
including MyoD, Myf5 andmyogenin. In the presence of muscle
induction conditions, Pax3-MSC-derived myogenic progenitors
undergo final maturation by differentiating into multinucleated
myotubes (Figs. 3A–E). Previous work has demonstrated im-
proved muscle differentiation of MSCs in the presence of Notch
signaling [21]. Here the effect of Pax3 on muscle differentiation
seems independentof theNotchpathway, asnoup-regulationof
Hes1 and Hes5, downstream targets of Notch, was observed
(Fig. 8). Interestingly, activation of the myogenic program by
Pax3 occurs at the expense of other mesenchymal lineages, as
observed by its inhibitory effect on adipogenesis, osteogenesis,
and chondrogenesis (Figs. 4A–B). Such transcriptional modula-
tionhas beenpreviouslydescribed formesenchymal lineages, in
particular for fat and bone. For instance, it has been demon-
strated that haploinsufficency of PPARγ-2, a key transcription
factor for adipogenesis, leads to osteogenesis by increased
osteoblast formation [38,39]. Conversely, with aging, commit-
ment of murine MSCs to the adipogenic lineage is enhanced at
the expense of osteogenesis [40], a phenotype which correlates
with increased levels of PPARγ-2 [40].While PPARγ-2 is essential
to drive adipogenesis fromMSCs [38,43], Runx2 (Cbfa1) seems to
be the key player for osteoblast differentiation [41–43]. Our
results show that Pax3 overexpression blocks adipogenesis,bjected to 2 rounds of Pax3 infection. BEND3-Pax3 cells were
P+ cells were sorted, as described in Fig. 4A.i, and cultured in
or Pax3, comparing 1 vs 2 round of Pax3 infection. (B) Gene
rowing in MSC expansion medium. RNA was isolated from
n of specific myogenic markers by real time RT-PCR, in which
profile remained the same even when cells were subjected to
spective cells cultured under several muscle induction
S; #2, MSC expansion medium containing no growth factors;
) indicate standard deviations from two independent
lls were used as positive control.
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PPARγ-2 and Cbfa-1.
Importantly, Pax3 enablesmuscle commitment specifically
in MSCs. Despite Pax3 overexpression, endothelial cells fail to
activate the myogenic program. Although Pax3 expression in
fibroblasts results in activation of MRFs, this is not accom-
panied by morphological changes typical of myogenic pro-
genitors or myotubes (Fig. 6C). Our results show that under
Pax3 activation only MSCs give rise to myogenic progenitors
capable of undergoing final maturation in vitro. This cell type-
selective effect of Pax3 is also observed during embryogenesis,
since despite being expressed in the neural tube, Pax3 does not
cause myogenesis to occur at this site.
Taken together, our data reveal the potential of regulating
transcriptional pathways to direct differentiation of adult
stem cells.Acknowledgments
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